Biogen Inc. (BIIB): Price and Financial Metrics
GET POWR RATINGS... FREE!
BIIB POWR Grades
- BIIB scores best on the Value dimension, with a Value rank ahead of 96.1% of US stocks.
- The strongest trend for BIIB is in Quality, which has been heading down over the past 177 days.
- BIIB ranks lowest in Momentum; there it ranks in the 32nd percentile.
BIIB Stock Summary
- BIIB has a market capitalization of $39,015,458,989 -- more than approximately 94.31% of US stocks.
- BIOGEN INC's stock had its IPO on September 17, 1991, making it an older stock than 84.76% of US equities in our set.
- Over the past twelve months, BIIB has reported earnings growth of 128.75%, putting it ahead of 89% of US stocks in our set.
- If you're looking for stocks that are quantitatively similar to BIOGEN INC, a group of peers worth examining would be EA, BGNE, STM, GRMN, and BIDU.
- BIIB's SEC filings can be seen here. And to visit BIOGEN INC's official web site, go to www.biogen.com.
BIIB Valuation Summary
- BIIB's price/earnings ratio is 12.8; this is 44.83% lower than that of the median Healthcare stock.
- Over the past 243 months, BIIB's EV/EBIT ratio has gone down 11.8.
Below are key valuation metrics over time for BIIB.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| BIIB | 2023-03-24 | 3.8 | 2.9 | 12.8 | 11.5 |
| BIIB | 2023-03-23 | 3.8 | 2.9 | 12.6 | 11.3 |
| BIIB | 2023-03-22 | 3.7 | 2.8 | 12.4 | 11.1 |
| BIIB | 2023-03-21 | 3.8 | 2.9 | 12.6 | 11.3 |
| BIIB | 2023-03-20 | 3.8 | 2.9 | 12.7 | 11.4 |
| BIIB | 2023-03-17 | 3.7 | 2.8 | 12.5 | 11.2 |
BIIB Growth Metrics
- Its 5 year revenue growth rate is now at 25.06%.
- The 4 year cash and equivalents growth rate now stands at 180.44%.
- The year over year revenue growth rate now stands at -14.16%.
The table below shows BIIB's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-12-31 | 10,173.4 | 1,384.3 | 3,046.9 |
| 2022-09-30 | 10,363.2 | 2,397.6 | 2,864.7 |
| 2022-06-30 | 10,633.6 | 2,541.9 | 2,059.2 |
| 2022-03-31 | 10,819.5 | 3,032.7 | 1,449.7 |
| 2021-12-31 | 10,981.7 | 3,639.9 | 1,556.1 |
| 2021-09-30 | 11,100.5 | 2,434.5 | 1,545.8 |
BIIB's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- BIIB has a Quality Grade of B, ranking ahead of 87.69% of graded US stocks.
- BIIB's asset turnover comes in at 0.459 -- ranking 97th of 680 Pharmaceutical Products stocks.
- ZSAN, ARMP, and HGEN are the stocks whose asset turnover ratios are most correlated with BIIB.
The table below shows BIIB's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-09-30 | 0.459 | 0.825 | 0.064 |
| 2021-06-30 | 0.478 | 0.839 | 0.098 |
| 2021-03-31 | 0.510 | 0.855 | 0.206 |
| 2020-12-31 | 0.531 | 0.866 | 0.283 |
| 2020-09-30 | 0.550 | 0.876 | 0.369 |
| 2020-06-30 | 0.545 | 0.880 | 0.415 |
BIIB Price Target
For more insight on analysts targets of BIIB, see our BIIB price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $417.00 | Average Broker Recommendation | 1.64 (Moderate Buy) |
BIIB Stock Price Chart Interactive Chart >
BIIB Price/Volume Stats
| Current price | $270.25 | 52-week high | $311.88 |
| Prev. close | $269.98 | 52-week low | $187.16 |
| Day low | $268.78 | Volume | 560,270 |
| Day high | $271.90 | Avg. volume | 998,654 |
| 50-day MA | $276.33 | Dividend yield | N/A |
| 200-day MA | $252.75 | Market Cap | 39.05B |
Biogen Inc. (BIIB) Company Bio
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide.(Source:Wikipedia)
Latest BIIB News From Around the Web
Below are the latest news stories about BIOGEN INC that investors may wish to consider to help them evaluate BIIB as an investment opportunity.
Ionis (IONS) Posts New Upbeat Data From Amyloidosis Drug StudyIonis (IONS) reports positive long-term phase III study data, supporting the benefits of eplontersen as a treatment for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN). |
Biogen Inc. (NASDAQ:BIIB) is a favorite amongst institutional investors who own 88%Key Insights Given the large stake in the stock by institutions, Biogen's stock price might be vulnerable to their... |
7 Blue-Chip Stocks Sitting in the Sweet SpotAlthough blue-chip stocks carry a reputation for being bulky and not exciting, these large enterprises can really move. |
Biogen Pops — But Ionis Hands Back Gains — After ALS Drug Wins A Key EndorsementBiogen stock jumped — as Ionis stock gave back early gains — after a FDA panel offered a mixed view of their ALS treatment. |
Biotech Stock Roundup: ALT Obesity Data, GILD Exercises Option, INCY Drug ApprovalIncyte's (INCY) skin cancer drug approval and Altimmune's obesity data are the key highlights from the biotech sector during the past week. |
BIIB Price Returns
| 1-mo | 0.09% |
| 3-mo | -1.38% |
| 6-mo | 2.26% |
| 1-year | 27.67% |
| 3-year | -8.93% |
| 5-year | -1.30% |
| YTD | -2.41% |
| 2022 | 15.42% |
| 2021 | -2.02% |
| 2020 | -17.48% |
| 2019 | -1.39% |
| 2018 | -5.54% |
Continue Researching BIIB
Want to see what other sources are saying about Biogen Inc's financials and stock price? Try the links below:Biogen Inc (BIIB) Stock Price | Nasdaq
Biogen Inc (BIIB) Stock Quote, History and News - Yahoo Finance
Biogen Inc (BIIB) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...